TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3742933

Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Labetalol (300 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30199451

Group type: EXPERIMENTAL
Intervention: Horizontal load training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Maximal strength training (squats and deadlifts)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Explosive strength training (power clean and high pull)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Vertical jumping exercises
Number of subjects: 45
Study: 29564847

Group type: EXPERIMENTAL
Intervention: Exercise training at maximal fat oxidation intensity (FATmax) for 1 hour/day, 3 days/week for 12 weeks
Number of subjects: 31
Study: 28887315

Group type: EXPERIMENTAL
Intervention: Sodium nitrate (600 mg; 7 mmol)
Number of subjects: 70
Study: 26121539

Group type: EXPERIMENTAL
Intervention: Laparoscopic Distal Pancreatectomy (LDP)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Open Distal Pancreatectomy (ODP)
Number of subjects: 112
Study: 24127467

Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Intensive medical care (IMC)
Number of subjects: 104
Study: 20484610

Group type: EXPERIMENTAL
Intervention: Gastric-retentive extended-release formulation of gabapentin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gastric-retentive extended-release formulation of gabapentin with food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Immediate-release formulation of gabapentin
Number of subjects: 0
Study: 18503113

Group type: EXPERIMENTAL
Intervention: Revascularization surgery
Number of subjects: 10
Study: 17003433

Group type: EXPERIMENTAL
Intervention: Ocular Response Analyzer (ORA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Goldmann Applanation Tonometry (GAT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Central Corneal Thickness (CCT)
Number of subjects: 48
Study: 12927650

Group type: EXPERIMENTAL
Intervention: Monetary incentives
Number of subjects: 96

Group type: COMPARATOR
Intervention: Outreach
Number of subjects: 96
Study: 11012558

Group type: COMPARATOR
Intervention: S 17092 100 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: S 17092 800 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: S 17092 1200 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: S 17092 (all doses)
Number of subjects: 36
Study: 8881815

Group type: EXPERIMENTAL
Intervention: 6 mg budesonide
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: 3 mg budesonide
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study: 1384078

Group type: EXPERIMENTAL
Intervention: i.v. opiate by signalled self-injection
Number of subjects: 6

Group type: COMPARATOR
Intervention: i.v. opiate by un-signalled infusion
Number of subjects: 6

Group type: COMPARATOR
Intervention: saline
Number of subjects: 6
Study: 4011463

Group type: EXPERIMENTAL
Intervention: Fluid restriction (8%-10% weight loss)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Fluid restriction (13%-15% weight loss)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: hsPDA presence
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Typical ductal murmur
Number of subjects: 50
Study: 31516731

Group type: EXPERIMENTAL
Intervention: Naproxen 375 mg + Lidocaine 2%
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo + Lidocaine 2%
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Naproxen 375 mg + Placebo
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo + Placebo
Number of subjects: 160
Study: 30424793

Group type: EXPERIMENTAL
Intervention: High illuminance lighting (1500-2000 lx)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard ambient fluorescent lighting
Number of subjects: 43
Study: 27940690

Group type: EXPERIMENTAL
Intervention: Neonatal hypoglycemia
Number of subjects: 745

Group type: COMPARATOR
Intervention: Normoglycemic controls
Number of subjects: 745
Study: 24859962

Group type: EXPERIMENTAL
Intervention: Fast track surgery (FTS)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Routine management (Control)
Number of subjects: 71
Study: 22313075

Group type: EXPERIMENTAL
Intervention: Ventilator hyperinflation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Manual hyperinflation
Number of subjects: 46
Study: 21030718

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 18728597

Group type: EXPERIMENTAL
Intervention: Collagen matrix during hemicraniectomy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Conventional procedure (Control)
Number of subjects: 34
Study: 15766617

Group type: EXPERIMENTAL
Intervention: Multicomponent Internet CME (mCME) intervention consisting of four case-based learning modules, tailored in real time, and included office-level feedback of chlamydia screening rates.
Number of subjects: 191

Group type: COMPARATOR
Intervention: Control group (comparison offices) without the mCME intervention.
Number of subjects: 191
Study: 12614927

Group type: EXPERIMENTAL
Intervention: Bilateral movement/stimulation group (active neuromuscular stimulation: 5 s/trial, 90 trials/day, biphasic waveform for 4 days over 2 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unilateral movement/stimulation group (active neuromuscular stimulation: 5 s/trial, 90 trials/day, biphasic waveform for 4 days over 2 weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bilateral movement/stimulation group
Number of subjects: 20
Study: 10194427

Group type: EXPERIMENTAL
Intervention: Stem cell factor (SCF) at 20 micrograms/kg/d plus Filgrastim at 10 micrograms/kg/d
Number of subjects: 203

Group type: COMPARATOR
Intervention: Filgrastim alone at 10 micrograms/kg/d
Number of subjects: 203
Study: 8669327

Group type: EXPERIMENTAL
Intervention: Complete hormone blockade (CHB)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Monotherapy (orchidectomy)
Number of subjects: 102
Study: 2228327

Group type: COMPARATOR
Intervention: Intramuscular atropine (0.02 mg/kg)
Number of subjects: 6
Study: 481057

Group type: EXPERIMENTAL
Intervention: Thalamonal
Number of subjects: 498

Group type: COMPARATOR
Intervention: Valium
Number of subjects: 498
Study: 31584144

Group type: EXPERIMENTAL
Intervention: mMitra voice messages (intervention group)
Number of subjects: 2016
Study: 29857497

Group type: EXPERIMENTAL
Intervention: HP diet with ≥4 weekly servings of lean beef (B)
Number of subjects: 120

Group type: COMPARATOR
Intervention: HP diet restricted in all red meats (NB)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (B and NB)
Number of subjects: 120
Study: 26417901

Group type: EXPERIMENTAL
Intervention: Sublingual liquid birch pollen preparation (SB) 3333 AUN/ml
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Sublingual liquid birch pollen preparation (SB) 10,000 AUN/ml
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Sublingual liquid birch pollen preparation (SB) 20,000 AUN/ml
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Sublingual liquid birch pollen preparation (SB) 40,000 AUN/ml
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 24271139

Group type: EXPERIMENTAL
Intervention: Intraoperative sRAGE levels
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: sRAGE kinetics
Number of subjects: 90

Group type: COMPARATOR
Intervention: Age and euroSCORE
Number of subjects: 90

Group type: COMPARATOR
Intervention: Preoperative sRAGE values
Number of subjects: 90

Group type: COMPARATOR
Intervention: 30-day mortality
Number of subjects: 90
Study: 22337315

Group type: EXPERIMENTAL
Intervention: Inspiratory exercise with elastic chest band (EG)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Inspiratory exercise without elastic chest band (CG)
Number of subjects: 16
Study: 19189065

Group type: EXPERIMENTAL
Intervention: TCI-Schnider
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TCI-Marsh
Number of subjects: 90

Group type: COMPARATOR
Intervention: MCI
Number of subjects: 90
Study: 17495826

Group type: EXPERIMENTAL
Intervention: Median mini-laparotomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Complete median laparotomy
Number of subjects: 40
Study: 15356671

Group type: EXPERIMENTAL
Intervention: 10% of energy from white wine
Number of subjects: 40

Group type: COMPARATOR
Intervention: 10% of energy from grape juice
Number of subjects: 40
Study: 11254918

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Fluvastatin 80 mg
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Lovastatin 80 mg
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 169

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 169
Study: 9511827

Group type: EXPERIMENTAL
Intervention: Antibody response against alpha‐toxin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Antibody response against teichoic acid
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Positive antibody response to at least one of the three antigens
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Complicated septicaemia (alpha-toxin response)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Uncomplicated septicaemia (alpha-toxin response)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Complicated septicaemia (teichoic acid response)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Uncomplicated septicaemia (teichoic acid response)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Complicated septicaemia (lipase response)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Uncomplicated septicaemia (lipase response)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Initial antibody levels
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: ELISA titres against alpha‐toxin
Number of subjects: 63
Study: 7798807

Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy with discriminant analysis
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Nailfold capillaroscopy
Number of subjects: 307
Study: 3366055

Group type: EXPERIMENTAL
Intervention: Different reinforcement conditions during drinking sessions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group that acquired tolerance most rapidly
Number of subjects: 0
Study: 30504318

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venetoclax and Rituximab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination therapies
Number of subjects: 0
Study: 26311397

Group type: EXPERIMENTAL
Intervention: Normal writing condition (pencil with polystyrene)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Impaired writing condition (pencil with steel)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Pointing condition (control)
Number of subjects: 51
Study: 24667662

Group type: EXPERIMENTAL
Intervention: Two-day regimen of dihydroartemisinin-piperaquine (total dose 360 mg dihydroartemisinin and 2880 mg piperaquine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Three-day regimen of dihydroartemisinin-piperaquine (total dose 360 mg dihydroartemisinin and 2880 mg piperaquine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Both regimens (two-day and three-day)
Number of subjects: 80
Study: 22475524

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0
Study: 20636866

Group type: EXPERIMENTAL
Intervention: Topical agents (specific agents not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-treatment (control)
Number of subjects: 0
Study: 16900483

Group type: EXPERIMENTAL
Intervention: All-trans-retinoic acid (ATRA) at 90 mg/m2/day in three divided doses for 3 consecutive days per week, combined with interferon-α2a (IFN-α2a) at 3 × 106 U/m2/day subcutaneously for 5 consecutive days per week in 4 week cycles.
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group not specified; no active control reported.
Number of subjects: 32
Study: 16212835

Group type: EXPERIMENTAL
Intervention: ADHD subtypes (severe combined and talkative)
Number of subjects: 1610

Group type: COMPARATOR
Intervention: Population prevalence of broadly defined mania
Number of subjects: 1610

Group type: EXPERIMENTAL
Intervention: Children and adolescents with ADHD
Number of subjects: 1610
Study: 12133654

Group type: EXPERIMENTAL
Intervention: 150 microg/kg ivermectin every 3 months
Number of subjects: 657

Group type: EXPERIMENTAL
Intervention: 400 then 800 microg/kg ivermectin every 3 months
Number of subjects: 657

Group type: COMPARATOR
Intervention: 150 microg/kg ivermectin yearly (reference group)
Number of subjects: 657
Study: 8842905

Group type: EXPERIMENTAL
Intervention: Postoperative intravenous ketorolac
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Patient controlled analgesia with morphine (0.015 mg/kg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No ketorolac
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ambulation on the first postoperative day
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Discharge within 2 days of surgery
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Long-term donor site morbidity
Number of subjects: 34
Study: 2180549

Group type: EXPERIMENTAL
Intervention: Cholecystokinin-tetrapeptide (CCK-4)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 6927982

Group type: EXPERIMENTAL
Intervention: Calcium glycerophosphate (experimental groups)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 31226322

Group type: EXPERIMENTAL
Intervention: Tamoxifen 10mg twice daily for 7 days starting 21 days after IUS insertion
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo twice daily for 7 days starting 21 days after IUS insertion
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 29150087

Group type: EXPERIMENTAL
Intervention: DAM (dexmedetomidine, methadone, alfaxalone)
Number of subjects: 44

Group type: COMPARATOR
Intervention: DKM (dexmedetomidine, methadone, ketamine)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study: 25545543

Group type: EXPERIMENTAL
Intervention: Single-frequency bioelectrical impedance analysis (SF-BIA)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Bioelectrical impedance spectroscopy (BIS)
Number of subjects: 41
Study: 23433769

Group type: EXPERIMENTAL
Intervention: AZD9668 60 mg twice daily for 4 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 21334098

Group type: EXPERIMENTAL
Intervention: 16 mg of daily oral dexamethasone for 2 days
Number of subjects: 200

Group type: COMPARATOR
Intervention: 50 mg of daily oral prednisone for 5 days
Number of subjects: 200
Study: 19962101

Group type: EXPERIMENTAL
Intervention: Essential oil lavandin (standard care plus essential oil lavandin)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sham (standard care plus jojoba oil)
Number of subjects: 150
Study: 17683960

Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 2972

Group type: COMPARATOR
Intervention: Carotid Angioplasty with or without Stent placement (CAS)
Number of subjects: 2972
Study: 15566514

Group type: EXPERIMENTAL
Intervention: TAE combined with PEIT
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: TAE combined with RFA
Number of subjects: 42

Group type: COMPARATOR
Intervention: PTA only (PEIT, 14; RFA, 6)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Overall recurrence
Number of subjects: 42

Group type: COMPARATOR
Intervention: Prior TAE
Number of subjects: 42
Study: 11210248

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation with lower total delivered energy (under 30 J)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser irradiation with higher energy settings
Number of subjects: 150

Group type: COMPARATOR
Intervention: Non-irradiated samples
Number of subjects: 150
Study: 10468681

Group type: EXPERIMENTAL
Intervention: Citric acid solution (200 mL, 75 mg of 13C-urea)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Orange juice (200 mL, 75 mg of 13C-urea)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Citric acid solution (200 mL, 50 mg of 13C-sodium acetate)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Orange juice (200 mL, 50 mg of 13C-sodium acetate)
Number of subjects: 50
Study: 7711762

Group type: EXPERIMENTAL
Intervention: Biomechanical Ankle Platform System (BAPS) training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study: 2676492

Group type: EXPERIMENTAL
Intervention: Water jet (WJ) laser
Number of subjects: 57

Group type: COMPARATOR
Intervention: Non-contact (NC) modality
Number of subjects: 57
Study: 65728

Group type: EXPERIMENTAL
Intervention: CVP (cyclophosphamide, vincristine, and prednisone)
Number of subjects: 62

Group type: COMPARATOR
Intervention: ABP (adriamycin, bleomycin, and prednisone)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: CVP (after cross-over)
Number of subjects: 62

Group type: COMPARATOR
Intervention: ABP (after cross-over)
Number of subjects: 62
Study: 31807750

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 19114

Group type: EXPERIMENTAL
Intervention: Untreated hypertension
Number of subjects: 19114

Group type: EXPERIMENTAL
Intervention: Factors related to treated but uncontrolled BP
Number of subjects: 19114
Study: 31201226

Group type: EXPERIMENTAL
Intervention: Video decision support tool
Number of subjects: 252
Study: 28166797

Group type: EXPERIMENTAL
Intervention: High-fat meal (HFAT; 50% fat)
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-carbohydrate meal (HCHO; 70% carbohydrate)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Habitual physical activity (HiPA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Habitual physical activity (LoPA)
Number of subjects: 40
Study: 25548849

Group type: EXPERIMENTAL
Intervention: Topical application of botulinum toxin A (BoNT A) after ablative fractional CO2 laser treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normal saline (control) after ablative fractional CO2 laser treatment
Number of subjects: 10
Study: 22993168

Group type: EXPERIMENTAL
Intervention: Varenicline tartrate plus Quitline‐counselling
Number of subjects: 392

Group type: COMPARATOR
Intervention: Quitline‐counselling alone
Number of subjects: 392
Study: 20929989

Group type: EXPERIMENTAL
Intervention: Screening for inducible ischemia
Number of subjects: 1123

Group type: COMPARATOR
Intervention: No screening for inducible ischemia
Number of subjects: 1123

Group type: EXPERIMENTAL
Intervention: UK Prospective Diabetes Study (UKPDS) risk engine
Number of subjects: 1123
Study: 20635764

Group type: EXPERIMENTAL
Intervention: Tenecteplase
Number of subjects: 0
Study: 16706244

Group type: EXPERIMENTAL
Intervention: Metronidazole 1% gel (once-daily application)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Azelaic acid 15% gel (twice-daily application)
Number of subjects: 160
Study: 14767168

Group type: EXPERIMENTAL
Intervention: Sodium fluoride gel
Number of subjects: 773

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 773
Study: 11713157

Group type: EXPERIMENTAL
Intervention: Cotinine-feedback, behaviorally based education intervention (n = 51)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Cotinine-feedback, behaviorally based education intervention (n = 60)
Number of subjects: 87
Study: 9325559

Group type: EXPERIMENTAL
Intervention: Clozapine treatment
Number of subjects: 10

Group type: COMPARATOR
Intervention: Ketamine infusion (placebo-controlled)
Number of subjects: 10
Study: 7496554

Group type: EXPERIMENTAL
Intervention: Acetaminophen up to 4 g/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NSAIDs (initially in lower analgesic doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonpharmacologic measures
Number of subjects: 0
Study: 2499187

Group type: EXPERIMENTAL
Intervention: 200 micrograms of misoprostol QID
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 100 micrograms of misoprostol QID
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 50 micrograms of misoprostol QID
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 30130627

Group type: EXPERIMENTAL
Intervention: Alfuzosin (2.5 mg immediate release)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Alfuzosin (10 mg extended release)
Number of subjects: 72
Study: 27692906

Group type: EXPERIMENTAL
Intervention: Sleeve Gastrectomy (SG)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Number of subjects: 72
Study: 26004888

Group type: EXPERIMENTAL
Intervention: High-dose selenium supplementation (Se+, n = 75)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard-dose selenium supplementation (Se-, n = 75)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High-dose selenium supplementation (Se+, n = 75) in SIRS patients
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard-dose selenium supplementation (Se-, n = 75) in SIRS patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: High-dose selenium supplementation (Se+, n = 75) in sepsis patients
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard-dose selenium supplementation (Se-, n = 75) in sepsis patients
Number of subjects: 150
Study: 22817768

Group type: EXPERIMENTAL
Intervention: 1 mg of lorazepam (LZ)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21705404

Group type: EXPERIMENTAL
Intervention: 5 mM yohimbine plus 1 mM propranolol (intervention)
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1 mM propranolol (control)
Number of subjects: 12
Study: 19105405

Group type: EXPERIMENTAL
Intervention: Combined treatment with coaxil
Number of subjects: 86

Group type: COMPARATOR
Intervention: Somatotropic monotherapy
Number of subjects: 86
Study: 16803842

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy (PMRT)
Number of subjects: 1951
Study: 15461995

Group type: EXPERIMENTAL
Intervention: Constant training (CST)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Interval training (SWEET)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control values
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Post-exercise recovery
Number of subjects: 10